1. Home
  2. LBRX vs OPRA Comparison

LBRX vs OPRA Comparison

Compare LBRX & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LB Pharmaceuticals Inc

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$47.00

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Opera Limited

OPRA

Opera Limited

HOLD

Current Price

$18.42

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRX
OPRA
Founded
2015
1996
Country
United States
Norway
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
LBRX
OPRA
Price
$47.00
$18.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$46.60
$21.50
AVG Volume (30 Days)
285.4K
347.3K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
4.61%
EPS Growth
98.22
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$21.29
Revenue Next Year
N/A
$15.34
P/E Ratio
N/A
$13.62
Revenue Growth
N/A
N/A
52 Week Low
$13.40
$11.71
52 Week High
$50.16
$21.06

Technical Indicators

Market Signals
Indicator
LBRX
OPRA
Relative Strength Index (RSI) 56.39 43.16
Support Level $21.90 $18.56
Resistance Level $49.65 $19.58
Average True Range (ATR) 2.02 0.60
MACD -0.53 -0.09
Stochastic Oscillator 30.43 35.66

Price Performance

Historical Comparison
LBRX
OPRA

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

About OPRA Opera Limited

Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.

Share on Social Networks: